Schor Chen — SEC Form 4 Insider Trading Activity

Summary

Updated Jul 16, 2026

Schor Chen has filed 2 SEC Form 4 filings across 2 companies in the last 90 days.

Profile

Chen Schor is the President and Chief Executive Officer of Adicet Bio, Inc., a clinical-stage biotechnology company focused on allogeneic gamma delta T cell therapies for cancer and other diseases. Based on SEC filings dated January 27, 2026, he has no reported purchases or sales in the filing, and leads the company in advancing programs such as ADI-001 and the preclinical candidate ADI-270.

Board memberships

• Adicet Bio, Inc.

Awards & honors

• Leading Adicet Bio's development of ADI-001, an allogeneic gamma delta T cell therapy.
• Overseeing the progression of the company's pipeline, including the preclinical ADI-270 candidate.
• Providing executive leadership during clinical development and regulatory milestone pursuit.

Recent Transactions

Companies — Last 90 Days

• Adicet Bio, Inc. (ACET) — 1 filings, last 2026-06-23
• Karyopharm Therapeutics Inc. (KPTI) — 1 filings, last 2026-05-26

Frequently Asked Questions

Who is Schor Chen?

Chen Schor is the President and Chief Executive Officer of Adicet Bio, Inc., a clinical-stage biotechnology company focused on allogeneic gamma delta T cell therapies for cancer and other diseases. Based on SEC filings dated January 27, 2026, he has no reported purchases or sales in the filing, and leads the company in advancing programs such as ADI-001 and the preclinical cand…

How many SEC Form 4 filings has Schor Chen submitted recently?

2 primary Form 4 filings in the last 90 days, covering 2 companies.

Where can I see all of Schor Chen's SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Learn More

• What is SEC Form 4?
• How to read insider buying signals
• Understanding Rule 10b5-1 trading plans
• Browse all insiders
• Most active insiders this week